OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hammers on the Potential Utility of HIF-2α Inhibitors in RCC

June 2nd 2021

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.

Dr. Lower on the Importance of Tucatinib Plus Capecitabine/Trastuzumab in HER2+ Breast Cancer

June 2nd 2021

Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.

Dr. Yacoub on Next Steps With Parsaclisib Plus Ruxolitinib in Myelofibrosis

June 1st 2021

Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.

Dr. Choti on Pursuing Chemotherapy Following Tumor Resection in Advanced CRC

June 1st 2021

Michael A. Choti, MD, discusses pursuing chemotherapy following tumor resection in advanced colorectal cancer.

Dr. Ross on Toxicity Concerns With Combination Therapies in EGFR+ NSCLC

June 1st 2021

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

Dr. Ghosh on the Role of Ide-Cel in Relapsed/Refractory Multiple Myeloma

June 1st 2021

Monalisa Ghosh, MD, discusses the role of idecabtagene vicleucel in relapsed/refractory multiple myeloma landscape.

Dr. Javle on the FDA Approval of Infigratinib in FGFR-Mutated Cholangiocarcinoma

May 28th 2021

Milind Javle, MD, discusses the FDA approval of infigratinib in FGFR-mutated cholangiocarcinoma.

Dr. Morgan on Optimizing Treatment in Ultra High–Risk Multiple Myeloma

May 27th 2021

Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer

May 26th 2021

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

Dr. Doroshow on Increasing Patient Accrual to Clinical Trials During the COVID-19 Pandemic

May 26th 2021

James H. Doroshow, MD, discusses strategies that were implemented to increase patient accrual to clinical trials during the COVID-19 pandemic.

Dr. Juárez Soto on the Rationale to Analyze the Latin American Subgroup of the TITAN Trial in mHSPC

May 26th 2021

Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.

Dr. Gallego on the Impact of COVID-19 on Cancer Care in Spain

May 26th 2021

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Dr. Sosa on Risk Factors for Thyroid Cancer

May 25th 2021

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

Dr. DeCaprio on Raising Awareness in Merkel Cell Carcinoma

May 25th 2021

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell Carcinoma

May 25th 2021

Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.

Dr. Chern on Future Research Directions in Ovarian Cancer

May 25th 2021

Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.

Dr. Strauss on Future Research Directions in SCLC

May 25th 2021

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

Dr. Lee on the Results of the REACH3 Trial in Chronic GVHD

May 24th 2021

Stephanie J. Lee, MD, MPH, discusses the results of the phase 3 REACH3 trial in chronic graft-vs-host disease.

Dr. Hutson on Safety Considerations With Cabozantinib in mRCC

May 24th 2021

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial Carcinoma

May 24th 2021

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.